Non-Small Cell Lung Cancer

About
Mappings

OncoTree: Non-Small Cell Lung Cancer (oncotree:NSCLC)

View API

Therapeutic response

Precision oncology relationships for therapeutic response involving this cancer type.

Type Biomarker(s) Cancer type Therapy(ies)
Sensitivity (+) KRAS p.G12C Non-Small Cell Lung Cancer Adagrasib FDA
Sensitivity (+) EGFR somatic variants Non-Small Cell Lung Cancer Afatinib FDA
Sensitivity (+) v::ALK Non-Small Cell Lung Cancer Alectinib FDA
Sensitivity (+) v::ALK Non-Small Cell Lung Cancer Alectinib FDA
Sensitivity (+) EGFR Exon 20 (Insertion) Non-Small Cell Lung Cancer Amivantamab, Carboplatin, Pemetrexed FDA
Sensitivity (+) EGFR Exon 20 (Insertion) Non-Small Cell Lung Cancer Amivantamab FDA
Sensitivity (+) PD-L1 >= 1% Non-Small Cell Lung Cancer Atezolizumab FDA
Sensitivity (+) PD-L1 >= 50% Non-Small Cell Lung Cancer Atezolizumab FDA
Sensitivity (+) PD-L1 >= 10% TIIC Non-Small Cell Lung Cancer Atezolizumab FDA
Sensitivity (+) Wild type ALK, Wild type EGFR Non-Small Cell Lung Cancer Atezolizumab, Bevacizumab, Carboplatin, Paclitaxel FDA
Sensitivity (+) Wild type ALK, Wild type EGFR Non-Small Cell Lung Cancer Atezolizumab, Carboplatin, Paclitaxel FDA
Sensitivity (+) EGFR somatic variants Non-Small Cell Lung Cancer Atezolizumab FDA
Sensitivity (+) v::ALK Non-Small Cell Lung Cancer Atezolizumab FDA
Sensitivity (+) BRAF p.V600E Non-Small Cell Lung Cancer Binimetinib, Encorafenib FDA
Sensitivity (+) v::ALK Non-Small Cell Lung Cancer Brigatinib FDA
Sensitivity (+) MET Exon 14 (Splice Site) Non-Small Cell Lung Cancer Capmatinib FDA
Sensitivity (+) MET Exon 14 (Deletion) Non-Small Cell Lung Cancer Capmatinib FDA
Sensitivity (+) Wild type ALK, Wild type EGFR, Wild type ROS1 Non-Small Cell Lung Cancer Carboplatin, Cemiplimab, Pemetrexed FDA
Sensitivity (+) PD-L1 >= 50%, Wild type ALK, Wild type EGFR, dMMR Non-Small Cell Lung Cancer Cemiplimab FDA
Sensitivity (+) v::ALK Non-Small Cell Lung Cancer Ceritinib FDA
Sensitivity (+) v::ALK Non-Small Cell Lung Cancer Crizotinib FDA
Sensitivity (+) v::ROS1 Non-Small Cell Lung Cancer Crizotinib FDA
Sensitivity (+) BRAF p.V600E Non-Small Cell Lung Cancer Dabrafenib, Trametinib FDA
Sensitivity (+) EGFR Exon 19 (Deletion) Non-Small Cell Lung Cancer Dacomitinib FDA
Sensitivity (+) EGFR p.L858R Non-Small Cell Lung Cancer Dacomitinib FDA
Sensitivity (+) Wild type ALK, Wild type EGFR Non-Small Cell Lung Cancer Carboplatin, Durvalumab, Pemetrexed, Tremelimumab FDA
Sensitivity (+) Wild type ALK, Wild type EGFR Non-Small Cell Lung Cancer Cisplatin, Durvalumab, Pemetrexed, Tremelimumab FDA
Sensitivity (+) Wild type ALK, Wild type EGFR Non-Small Cell Lung Cancer Carboplatin, Durvalumab, Gemcitabine, Tremelimumab FDA
Sensitivity (+) Wild type ALK, Wild type EGFR Non-Small Cell Lung Cancer Cisplatin, Durvalumab, Gemcitabine, Tremelimumab FDA
Sensitivity (+) Wild type ALK, Wild type EGFR Non-Small Cell Lung Cancer Carboplatin, Durvalumab, Nab-paclitaxel, Tremelimumab FDA
Sensitivity (+) BRAF p.V600E Non-Small Cell Lung Cancer Binimetinib, Encorafenib FDA
Sensitivity (+) v::ROS1 Non-Small Cell Lung Cancer Entrectinib FDA
Sensitivity (+) EGFR Exon 19 (Deletion) Non-Small Cell Lung Cancer Erlotinib FDA
Sensitivity (+) EGFR p.L858R Non-Small Cell Lung Cancer Erlotinib FDA
Sensitivity (+) EGFR Exon 19 (Deletion) Non-Small Cell Lung Cancer Gefitinib FDA
Sensitivity (+) EGFR p.L858R Non-Small Cell Lung Cancer Gefitinib FDA
Sensitivity (+) PD-L1 >= 1%, Wild type ALK, Wild type EGFR Non-Small Cell Lung Cancer Ipilimumab, Nivolumab FDA
Sensitivity (+) Wild type ALK, Wild type EGFR Non-Small Cell Lung Cancer Carboplatin, Ipilimumab, Nivolumab, Pemetrexed FDA
Sensitivity (+) Wild type ALK, Wild type EGFR Non-Small Cell Lung Cancer Cisplatin, Ipilimumab, Nivolumab, Pemetrexed FDA
Sensitivity (+) Wild type ALK, Wild type EGFR Non-Small Cell Lung Cancer Carboplatin, Ipilimumab, Nivolumab, Paclitaxel FDA
Sensitivity (+) v::ALK Non-Small Cell Lung Cancer Lorlatinib FDA
Sensitivity (+) EGFR Exon 20 (Insertion) Non-Small Cell Lung Cancer Mobocertinib FDA
Sensitivity (+) Wild type ALK, Wild type EGFR Non-Small Cell Lung Cancer Carboplatin, Nivolumab, Paclitaxel FDA
Sensitivity (+) Wild type ALK, Wild type EGFR Non-Small Cell Lung Cancer Cisplatin, Nivolumab, Pemetrexed FDA
Sensitivity (+) Wild type ALK, Wild type EGFR Non-Small Cell Lung Cancer Cisplatin, Gemcitabine, Nivolumab FDA
Sensitivity (+) EGFR Exon 19 (Deletion) Non-Small Cell Lung Cancer Osimertinib FDA
Sensitivity (+) EGFR p.L858R Non-Small Cell Lung Cancer Osimertinib FDA
Sensitivity (+) EGFR Exon 19 (Deletion) Non-Small Cell Lung Cancer Osimertinib FDA
Sensitivity (+) EGFR p.L858R Non-Small Cell Lung Cancer Osimertinib FDA
Sensitivity (+) EGFR p.L858R Non-Small Cell Lung Cancer Cisplatin, Osimertinib, Pemetrexed FDA
Sensitivity (+) EGFR p.L858R Non-Small Cell Lung Cancer Carboplatin, Osimertinib, Pemetrexed FDA
Sensitivity (+) EGFR Exon 19 (Deletion) Non-Small Cell Lung Cancer Carboplatin, Osimertinib, Pemetrexed FDA
Sensitivity (+) EGFR Exon 19 (Deletion) Non-Small Cell Lung Cancer Cisplatin, Osimertinib, Pemetrexed FDA
Sensitivity (+) EGFR p.T790M Non-Small Cell Lung Cancer Osimertinib FDA
Sensitivity (+) Wild type ALK, Wild type EGFR Non-Small Cell Lung Cancer Carboplatin, Pembrolizumab, Pemetrexed FDA
Sensitivity (+) Wild type ALK, Wild type EGFR Non-Small Cell Lung Cancer Cisplatin, Pembrolizumab, Pemetrexed FDA
Sensitivity (+) PD-L1 >= 1%, Wild type ALK, Wild type EGFR Non-Small Cell Lung Cancer Pembrolizumab FDA
Sensitivity (+) PD-L1 >= 1% Non-Small Cell Lung Cancer Pembrolizumab FDA
Sensitivity (+) v::RET Non-Small Cell Lung Cancer Pralsetinib FDA
Sensitivity (+) EGFR Exon 19 (Deletion) Non-Small Cell Lung Cancer Erlotinib, Ramucirumab FDA
Sensitivity (+) EGFR p.L858R Non-Small Cell Lung Cancer Erlotinib, Ramucirumab FDA
Sensitivity (+) v::ROS1 Non-Small Cell Lung Cancer Repotrectinib FDA
Sensitivity (+) v::RET Non-Small Cell Lung Cancer Selpercatinib FDA
Sensitivity (+) KRAS p.G12C Non-Small Cell Lung Cancer Sotorasib FDA
Sensitivity (+) MET Exon 14 (Splice Site) Non-Small Cell Lung Cancer Tepotinib FDA
Sensitivity (+) MET Exon 14 (Deletion) Non-Small Cell Lung Cancer Tepotinib FDA
Sensitivity (+) BRAF p.V600E Non-Small Cell Lung Cancer Dabrafenib, Trametinib FDA
Sensitivity (+) ERBB2 oncogenic variants Non-Small Cell Lung Cancer Trastuzumab deruxtecan FDA
Sensitivity (+) Wild type ALK, Wild type EGFR Non-Small Cell Lung Cancer Carboplatin, Durvalumab, Pemetrexed, Tremelimumab FDA
Sensitivity (+) Wild type ALK, Wild type EGFR Non-Small Cell Lung Cancer Cisplatin, Durvalumab, Pemetrexed, Tremelimumab FDA
Sensitivity (+) Wild type ALK, Wild type EGFR Non-Small Cell Lung Cancer Carboplatin, Durvalumab, Gemcitabine, Tremelimumab FDA
Sensitivity (+) Wild type ALK, Wild type EGFR Non-Small Cell Lung Cancer Cisplatin, Durvalumab, Gemcitabine, Tremelimumab FDA
Sensitivity (+) Wild type ALK, Wild type EGFR Non-Small Cell Lung Cancer Carboplatin, Durvalumab, Nab-paclitaxel, Tremelimumab FDA
Sensitivity (+) EGFR Exon 19 (Deletion) Non-Small Cell Lung Cancer Osimertinib FDA
Sensitivity (+) EGFR p.L858R Non-Small Cell Lung Cancer Osimertinib FDA
Sensitivity (+) EGFR Exon 19 (Deletion) Non-Small Cell Lung Cancer Amivantamab, Lazertinib FDA
Sensitivity (+) EGFR p.L858R Non-Small Cell Lung Cancer Amivantamab, Lazertinib FDA
Sensitivity (+) EGFR Exon 19 (Deletion) Non-Small Cell Lung Cancer Amivantamab, Lazertinib FDA
Sensitivity (+) EGFR p.L858R Non-Small Cell Lung Cancer Amivantamab, Lazertinib FDA
Sensitivity (+) EGFR Exon 19 (Deletion) Non-Small Cell Lung Cancer Amivantamab, Carboplatin, Pemetrexed FDA
Sensitivity (+) EGFR p.L858R Non-Small Cell Lung Cancer Amivantamab, Carboplatin, Pemetrexed FDA
Sensitivity (+) Wild type ALK, Wild type EGFR Non-Small Cell Lung Cancer Carboplatin, Durvalumab, Paclitaxel FDA
Sensitivity (+) Wild type ALK, Wild type EGFR Non-Small Cell Lung Cancer Cisplatin, Durvalumab, Gemcitabine FDA
Sensitivity (+) Wild type ALK, Wild type EGFR Non-Small Cell Lung Cancer Cisplatin, Durvalumab, Pemetrexed FDA
Sensitivity (+) Wild type ALK, Wild type EGFR Non-Small Cell Lung Cancer Carboplatin, Durvalumab, Pemetrexed FDA
Sensitivity (+) PD-L1 >= 1% Non-Small Cell Lung Cancer Ipilimumab, Nivolumab FDA
Sensitivity (+) Wild type ALK, Wild type EGFR Non-Small Cell Lung Cancer Carboplatin, Ipilimumab, Nivolumab, Pemetrexed FDA
Sensitivity (+) Wild type ALK, Wild type EGFR Non-Small Cell Lung Cancer Cisplatin, Ipilimumab, Nivolumab, Pemetrexed FDA
Sensitivity (+) Wild type ALK, Wild type EGFR Non-Small Cell Lung Cancer Carboplatin, Ipilimumab, Nivolumab, Paclitaxel FDA
Sensitivity (+) v::NRG1 Non-Small Cell Lung Cancer Zenocutuzumab FDA
Sensitivity (+) v::ALK Non-Small Cell Lung Cancer Ensartinib FDA
Sensitivity (+) v::ROS1 Non-Small Cell Lung Cancer Taletrectinib FDA
Sensitivity (+) EGFR somatic variants Non-Small Cell Lung Cancer Datopotamab deruxtecan FDA
Sensitivity (+) EGFR Exon 19 (Deletion) Non-Small Cell Lung Cancer Datopotamab deruxtecan FDA
Sensitivity (+) EGFR p.L858R Non-Small Cell Lung Cancer Datopotamab deruxtecan FDA
Sensitivity (+) EGFR p.T790M Non-Small Cell Lung Cancer Datopotamab deruxtecan FDA
Sensitivity (+) HER2-negative, PR positive Non-Small Cell Lung Cancer Datopotamab deruxtecan FDA
Sensitivity (+) EGFR Exon 20 (Insertion) Non-Small Cell Lung Cancer Sunvozertinib FDA
Sensitivity (+) v::ALK Non-Small Cell Lung Cancer Alectinib HC
Sensitivity (+) v::ALK Non-Small Cell Lung Cancer Brigatinib HC
Sensitivity (+) v::ROS1 Non-Small Cell Lung Cancer Repotrectinib HC
Sensitivity (+) EGFR somatic variants Non-Small Cell Lung Cancer Afatinib HC
Sensitivity (+) EGFR oncogenic variants Non-Small Cell Lung Cancer Afatinib HC
Sensitivity (+) Wild type ALK, Wild type EGFR Non-Small Cell Lung Cancer Carboplatin, Durvalumab, Tremelimumab HC
Sensitivity (+) EGFR Exon 19 (Deletion) Non-Small Cell Lung Cancer Gefitinib HC
Sensitivity (+) EGFR p.L858R Non-Small Cell Lung Cancer Gefitinib HC
Sensitivity (+) EGFR oncogenic variants Non-Small Cell Lung Cancer Gefitinib HC
Sensitivity (+) PD-L1 >= 1%, Wild type ALK, Wild type EGFR Non-Small Cell Lung Cancer Pembrolizumab HC
Sensitivity (+) PD-L1 >= 1% Non-Small Cell Lung Cancer Pembrolizumab HC
Sensitivity (+) EGFR Exon 19 (Deletion) Non-Small Cell Lung Cancer Amivantamab, Lazertinib HC
Sensitivity (+) EGFR p.L858R Non-Small Cell Lung Cancer Amivantamab, Lazertinib HC
Sensitivity (+) Wild type ALK, Wild type EGFR, Wild type ROS1 Non-Small Cell Lung Cancer Carboplatin, Cemiplimab, Pemetrexed HC
Sensitivity (+) PD-L1 >= 50%, Wild type ALK, Wild type EGFR, Wild type ROS1 Non-Small Cell Lung Cancer Cemiplimab HC
Sensitivity (+) v::ALK Non-Small Cell Lung Cancer Lorlatinib HC
Sensitivity (+) v::ALK Non-Small Cell Lung Cancer Lorlatinib HC
Sensitivity (+) KRAS p.G12C Non-Small Cell Lung Cancer Sotorasib HC
Sensitivity (+) BRAF p.V600E Non-Small Cell Lung Cancer Dabrafenib, Trametinib HC
Sensitivity (+) PD-L1 >= 1%, Wild type ALK, Wild type EGFR Non-Small Cell Lung Cancer Ipilimumab, Nivolumab HC
Sensitivity (+) v::RET Non-Small Cell Lung Cancer Selpercatinib HC
Sensitivity (+) v::ROS1 Non-Small Cell Lung Cancer Entrectinib HC
Sensitivity (+) EGFR Exon 19 (Deletion) Non-Small Cell Lung Cancer Amivantamab, Carboplatin, Pemetrexed HC
Sensitivity (+) EGFR p.L858R Non-Small Cell Lung Cancer Amivantamab, Carboplatin, Pemetrexed HC
Sensitivity (+) EGFR Exon 20 (Insertion) Non-Small Cell Lung Cancer Amivantamab, Carboplatin, Pemetrexed HC
Sensitivity (+) EGFR Exon 20 (Insertion) Non-Small Cell Lung Cancer Amivantamab HC
Sensitivity (+) MET Exon 14 (Splice Site) Non-Small Cell Lung Cancer Capmatinib HC
Sensitivity (+) MET Exon 14 (Deletion) Non-Small Cell Lung Cancer Capmatinib HC
Sensitivity (+) BRAF p.V600E Non-Small Cell Lung Cancer Dabrafenib, Trametinib HC
Sensitivity (+) EGFR Exon 19 (Deletion) Non-Small Cell Lung Cancer Osimertinib HC
Sensitivity (+) EGFR p.L858R Non-Small Cell Lung Cancer Osimertinib HC
Sensitivity (+) EGFR Exon 19 (Deletion) Non-Small Cell Lung Cancer Osimertinib HC
Sensitivity (+) EGFR p.L858R Non-Small Cell Lung Cancer Osimertinib HC
Sensitivity (+) EGFR Exon 19 (Deletion) Non-Small Cell Lung Cancer Osimertinib HC
Sensitivity (+) EGFR p.L858R Non-Small Cell Lung Cancer Osimertinib HC
Sensitivity (+) EGFR p.L858R Non-Small Cell Lung Cancer Cisplatin, Osimertinib, Pemetrexed HC
Sensitivity (+) EGFR p.L858R Non-Small Cell Lung Cancer Carboplatin, Osimertinib, Pemetrexed HC
Sensitivity (+) EGFR Exon 19 (Deletion) Non-Small Cell Lung Cancer Carboplatin, Osimertinib, Pemetrexed HC
Sensitivity (+) EGFR Exon 19 (Deletion) Non-Small Cell Lung Cancer Cisplatin, Osimertinib, Pemetrexed HC
Sensitivity (+) EGFR p.T790M Non-Small Cell Lung Cancer Osimertinib HC
Sensitivity (+) PD-L1 >= 50% Non-Small Cell Lung Cancer Atezolizumab HC
Sensitivity (+) PD-L1 >= 50%, Wild type ALK, Wild type EGFR Non-Small Cell Lung Cancer Atezolizumab HC
Sensitivity (+) PD-L1 >= 10% TIIC, Wild type ALK, Wild type EGFR Non-Small Cell Lung Cancer Atezolizumab HC
Sensitivity (+) MET Exon 14 (Splice Site) Non-Small Cell Lung Cancer Tepotinib HC
Sensitivity (+) MET Exon 14 (Deletion) Non-Small Cell Lung Cancer Tepotinib HC
Sensitivity (+) v::ALK Non-Small Cell Lung Cancer Crizotinib HC
Sensitivity (+) v::ROS1 Non-Small Cell Lung Cancer Crizotinib HC
Sensitivity (+) PD-L1 >= 1%, Wild type ALK, Wild type EGFR Non-Small Cell Lung Cancer Ipilimumab, Nivolumab HC
Sensitivity (+) Wild type ALK, Wild type EGFR Non-Small Cell Lung Cancer Cisplatin, Ipilimumab, Nivolumab, Pemetrexed HC
Sensitivity (+) v::ALK Non-Small Cell Lung Cancer Ceritinib HC
Sensitivity (+) v::ALK Non-Small Cell Lung Cancer Ceritinib HC